Alkermes Stock Forecast
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALKS analyst consensus
Consensus (20 analysts)
buy
Avg. price target
$57.74+28.48%
- Strong buy 3
- Buy 12
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Alkermes (2026-11-21), 15 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $57.74, with a high estimate of $83.00 and a low estimate of $38.00. The average target implies upside of 28.5% from the current price of $44.94.
The spread between the highest and lowest targets is 118.4%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALKS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 15% |
| Buy | 12 | 60% |
| Hold | 4 | 20% |
| Sell | 0 | 0% |
| Strong sell | 1 | 5% |
Ratings as of 2026-11-21.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $38.00 | -15.44% |
| Average target | $57.74 | +28.48% |
| High target | $83.00 | +84.69% |